Pharmaceutical Sector
warning: Creating default object from empty value in /home/topnewae/public_html/topnewsae/modules/taxonomy/taxonomy.pages.inc on line 33.

Teva Gets Green Signal to Acquire Actavis with Divestiture of Seventy Nine Existing and Future Drugs

Teva Gets Green Signal to Acquire Actavis with Divestiture of Seventy Nine Exist

Teva Pharmaceutical Industries Ltd got a green signal from the U.S. Federal Trade Commission to buy Actavis Inc, Allergan Plc's generic drug-making unit for $40.5 billion as the companies agreed to divest seventy nine existing and future drugs. That includes antibiotics, weight-loss drugs, anesthetics as well as oral contraceptives. They are used in ADHD treatments, treatments for allergies, arthritis, diabetes, high blood pressure, cancer, mental illness, pain, Parkinson's disease and respiratory, skin and sleep disorders and others.

A Peek into Vertex Pharmaceuticals Inc Shares

A Peek into Vertex Pharmaceuticals Inc SharesVertex Pharmaceuticals Inc's director Joshua S. Boger sold 5,140 shares of Boston, Massachusetts based Vertex Pharmaceuticals stock on Wednesday, July 6th. The total transaction was $457,408.60 at an average price of $88.99.

After the sale the director currently owns 273,365 shares of the company's stock as disclosed in a legal filing with the SEC.

Regulus Therapeutics Inc Reports, FDA has put Clinical Hold on Investigational New Drug RG-101

Regulus Therapeutics Inc Reports, FDA has put Clinical Hold on Investigational N

Carlsbad, California based Regulus Therapeutics Inc. is a biopharmaceutical company that is involved in discovery and development of pioneering medicines which target microRNAs. The company announced it has received a verbal notice from the U. S. Food and Drug Administration (FDA) which says its Investigational New Drug RG-101, which aims at treating chronic hepatitis C virus infection, has been placed on clinical hold.

Sarepta Shares Rise as FDA Requests for Additional Information on Eteplirsen, a Duchenne Treatment

Sarepta Shares Rise as FDA Requests for Additional Information on Eteplirsen, a

On Monday, Sarepta Therapeutics Inc's shares spiked during late trading hours with news that the U.S. Food and Drug Administration has asked for more information from the drug maker regarding its experimental treatment for muscular dystrophy.

Sarepta's shares climbed a sharp thirty one percent during the afterhours trading to $21.05.

Valeant Pharmaceuticals Fail to File Timely10-Q Form Receive Default Notice

Valeant Pharmaceuticals Fail to File Timely10-Q Form Receive Default Notice

On Friday, Valeant Pharmaceuticals said it has received a default notice from two lenders. The company said it has defaulted on some debts following its failure to submit a public filing. That gives the troubled drug maker two months to make the matters right.

The company failed to file its first-quarter earnings statement which is also known as a 10-Q form, on time to the U. S. Securities and Exchange Commission.

An FDA Advisory Panel Approves Acadia’s Parkinson’s Antipsychotic Drug

An FDA Advisory Panel Approves Acadia’s Parkinson’s Antipsychotic Drug

An advisory panel to the U. S. FDA (Food and Drug Administration) rendered their support for Acadia Pharmaceuticals Inc's, Nuplazid; a drug for psychosis related to Parkinson's disease. Approximately forty percent of patients suffering from the condition experience Psychosis, which is characterized by hallucinations and delusions.

According to the panel, the benefits of Nuplazid outweighed its risks. Twelve members in the panel out voted two, in favor of the treatment.

Valeant Shares Drop with News of Possible Earnings Restatement

Valeant Shares Drop with News of Possible Earnings Restatement

Valeant Pharmaceuticals International Inc, based in Laval, Canada has been facing a tough time since questions were raised regarding its accounting practices and its relation with Philidor Rx Services LLC, a mail-order pharmacy service provider.

People who have knowledge of the matter said, Valeant is expected to restate some of its past earnings limited to results from 2014 and 2015.

Syndicate content